Arbutus Biopharma Corporation share price logo

Arbutus Biopharma Corporation

NASDAQ: ABUS

Small Cap

$4.55

+0.12

(+2.71%)

as on

Arbutus Biopharma Corporation Stock Performance

as on June 19, 2026 at 2:15 pm IST

  • Day's Low

    Day's High

    $4.46
    $4.65
    downward going graph

    1.98%

    Downside

    2.20%

    Upside

    downward going graph

  • 52 Week's Low

    52 Week's High

    $3.04
    $5.10
    downward going graph

    33.19%

    Downside

    12.09%

    Upside

    downward going graph

Arbutus Biopharma Corporation share price movements today

Previous Close
$4.43
Open
$4.51
Volume
2.9M
Day's Low - High
$4.46 - $4.65
52 Week Low - High
$3.04 - $5.10

Arbutus Biopharma Corporation Historical Returns

1 Month Return
+ 8.33 %
3 Month Return
+ 4.12 %
1 Year Return
+ 31.12 %
3 Year Return
+ 82.73 %
5 Year Return
+ 40 %

Arbutus Biopharma Corporation Stock Fundamentals & Key Indicators

Check Arbutus Biopharma Corporation market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.

Market Cap

$891.9M

EPS (TTM)

-0.219

Dividend Yield

0.00%

Quarterly Earnings Growth YOY

0.00%

PE Ratio (TTM)

5.44

Industry PE ratio

-3.7464601769911505

PEG Ratio

0

EBITDA

155.1M

Revenue (TTM)

191.4M

Profit Margin

83.95%

Return On Equity TTM

94.73%

Arbutus Biopharma Corporation Stock Valuation

Track how Arbutus Biopharma Corporation P/E has moved over time to understand its valuation trends.

Arbutus Biopharma Corporation in the last 5 years

  • Overview

  • Trends

Lowest (-18.45x)

December 31, 2025

Industry (-3.75x)

June 19, 2026

Today (5.44x)

June 19, 2026

Highest (3.88x)

March 31, 2026

LowHigh

Today’s Price to Earnings Ratio: 5.44x

Arbutus Biopharma Corporation vs Peer Comparison

Compare market cap, revenue, PE, and other key metrics of Arbutus Biopharma Corporation with its industry peers.

Company
Analyst View
Market Cap
5 Years Return %PE RatioProfit Margin %Dividend Yield %
Arbutus Biopharma Corporation image
Arbutus Biopharma Corporation
BUY$891.9M40%5.4483.95%NA
Alnylam Pharmaceuticals Inc. image
Alnylam Pharmaceuticals Inc.
BUY$37.7B57.21%71.2112.55%NA
Vertex Pharmaceuticals Inc. image
Vertex Pharmaceuticals Inc.
BUY$116.5B140.42%27.2235.51%NA
Regeneron Pharmaceuticals Inc. image
Regeneron Pharmaceuticals Inc.
BUY$63.7B13.39%14.8529.65%0.58%

Stock Returns calculator for Arbutus Biopharma Corporation Stock including INR - Dollar returns

The Arbutus Biopharma Corporation stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Impact: The bonus return you make when the US Dollar rises against the Rupee; calculated on the full amount you walk away with, not just what you invested in.

Investment Value

₹1,00,000

  • 1Y

  • 3Y

  • 5Y

  • 7Y

  • 10Y

Arbutus Biopharma Corporation investment value today

Current value as on today

₹1,42,831

Returns

₹42,831

(+42.83%)

Returns from Arbutus Biopharma Corporation Stock

₹31,124 (+31.12%)

Dollar Impact

₹11,707 (+11.71%)

Analyst Recommendation on Arbutus Biopharma Corporation Stock

Based on 11 analysts

BUY

81.82%

Buy

18.18%

Hold

0.00%

Sell

Based on 11 analysts, 81.82% of analysts recommend a 'BUY' rating for Arbutus Biopharma Corporation. Average target price of $5.09

Arbutus Biopharma Corporation Share Price Target

Get share price movements and forecasts by analysts on Arbutus Biopharma Corporation.

What analysts predicted

10.61%UPSIDE

Target Price

$5.09

Current Price

$4.55

Analyzed by

11 Analysts

Target

$5.09

Arbutus Biopharma Corporation target price $5.09, a slight upside of 10.61% compared to current price of $4.55. According to 11 analysts rating.

Indian Investors' Interest in Arbutus Biopharma Corporation Stock

Search interest for Arbutus Biopharma Corporation Stock has increased by 194% in the last 30 days, reflecting an upward trend in search activity.

Time period: to

Change:194% versus previous 30 day period

Arbutus Biopharma Corporation Quarterly Profit & Loss

All numbers in Millions USD

Dec 2023
Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Total Revenue
2
1
1
1
1
1
10
0
1
179
Gross Profit
-15
1
1
1
-7
-7
10
0
1
179
Operating Income
-20
-19
-21
-21
-13
-34
1
-8
-7
169
EBITDA
-20
-17
-19
-19
-15
-24
2
-7
-3
169
Interest Expense
0
0
0
0
0
0
0
0
0
0
Depreciation
0
0
0
0
0
0
0
0
0
0
Income Before Tax
-19
-17
-19
-19
-12
-24
2
-7
-3
169
Income Tax Expense
1
0
0
-
-
-
-
-
-
-
Net Income
-19
-17
-19
-19
-12
-24
2
-7
-3
169
Net Profit Margin
-900.33%
-1166.78%
-1146.93%
-1472.52%
-796.19%
-1390.36%
23.49%
-1463.52%
-357.37%
94.73%

Arbutus Biopharma Corporation Annual Profit & Loss

All numbers in Millions USD

Dec 2016
Dec 2017
Dec 2018
Dec 2019
Dec 2020
Dec 2021
Dec 2022
Dec 2023
Dec 2024
Dec 2025
Total Revenue
1
10
5
6
6
10
39
18
6
14
Gross Profit
-59
-52
-52
-51
-40
10
39
18
6
13
Operating Income
-491
-110
-89
-143
-57
-73
-65
-78
-76
-27
EBITDA
-488
-106
-58
-162
-57
-71
-61
-70
-68
-33
Interest Expense
1
0
0
2
4
2
1
0
0
0
Depreciation
-
2
2
2
1
1
1
1
1
0
Income Before Tax
-489
-108
-61
-166
-63
-76
-65
-72
-69
-33
Income Tax Expense
-105
-24
-4
-12
1
1
4
0
-
-
Net Income
-384
-84
-57
-153
-63
-76
-69
-72
-69
-33
Net Profit Margin
-25606.67%
-788.79%
-967.80%
-2557.36%
-921.97%
-693.91%
-178.01%
-401.57%
-1133.04%
-237.88%

Arbutus Biopharma Corporation Quarterly Cash Flow

All numbers in Millions USD

Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Net Income
-17
-19
-19
-12
-24
2
-7
-3
169
Operating Cash Flow
-19
-14
-20
-10
-13
-15
-5
-4
-8
Investing Cash Flow
11
9
-11
13
11
15
-10
-1
2
Financing Cash Flow
24
24
1
1
2
0
0
1
11
Change in Cash
16
19
-30
4
0
0
-15
-4
5

Arbutus Biopharma Corporation Annual Cash Flow

All numbers in Millions USD

Dec 2017
Dec 2018
Dec 2019
Dec 2020
Dec 2021
Dec 2022
Dec 2023
Dec 2024
Dec 2025
Net Income
-84
-57
-153
-63
-76
-69
-72
-69
-33
Operating Cash Flow
-48
-67
-71
-51
-67
-35
-85
-64
-39
Investing Cash Flow
27
-4
28
-14
-12
-74
50
22
15
Financing Cash Flow
49
55
37
86
137
31
30
51
5
Change in Cash
30
-17
-5
20
57
-78
-4
10
-18

Global Institutional Holdings in Arbutus Biopharma Corporation

Funds
Holdings
Northern Trust Corp
0.65%
ADAR1 Capital Management LLC
1.59%
Charles Schwab Investment Management Inc
0.71%
Two Seas Capital LP
9.39%
Vanguard Group Inc
4.68%
See all

Insights on Arbutus Biopharma Corporation

Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

  • imgPOSITIVE IMPACT

    Best in 3 Years

    img

    In the last 3 years, ABUS has outperformed top 5 stocks with highest market-cap in its industry

  • imgPOSITIVE IMPACT

    Price Rise

    img

    In the last 7 days, ABUS stock has moved up by 6.8%

  • imgPOSITIVE IMPACT

    Profit Spike

    img

    Netprofit is up for the last 3 quarters, -7.74M → 169.69M (in $), with an average increase of 104.2% per quarter

  • imgPOSITIVE IMPACT

    Revenue Rich

    img

    Revenue is up for the last 3 quarters, 529.0K → 179.12M (in $), with an average increase of 74.5% per quarter

  • imgPOSITIVE IMPACT

    Best in 1 Year

    img

    In the last 1 year, ABUS has outperformed top 5 stocks with highest market-cap in its industry

About Arbutus Biopharma Corporation

Arbutus Biopharma Corporation, a clinical-stage biopharmaceutical company, develops novel therapeutics for infectious disease in the United States. Its chronic Hepatitis B virus product pipeline comprises Imdusiran, conjugated GalNAc, subcutaneously-delivered RNAi therapeutic product candidate which is in phase 2a clinical trials that suppresses all HBV antigens, including HBsAg expression; and AB-101, an oral PD-L1 inhibitor, which is in phase 1a/1b clinical trial that has the potential to reawaken patients' HBV-specific immune response by inhibiting PD-L1. The company has licensing agreement with Alnylam Pharmaceuticals, Inc. to develop and commercialize products with LNP delivery technology. The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in July 2015. Arbutus Biopharma Corporation was incorporated in 2005 is headquartered in Warminster, Pennsylvania.
OrganisationArbutus Biopharma Corporation
Headquarters701 Veterans Circle, Warminster, PA, United States, 18974
IndustryBiotechnology
CEOMs. Lindsay Androski J.D., M.B.A.
E-voting on sharesClick here to vote

Key Management of Arbutus Biopharma Corporation

Name

Title

Mr. Tuan Nguyen

Chief Financial Officer

Mr. Andrew J. Sung

General Counsel

Mr. R. Hector Mackay-Dunn B.A., J.D., L.L.B., Q.C.

Corporate Secretary

Ms. Lindsay Androski J.D., M.B.A.

President, CEO & Chairman

FAQs

What is Arbutus Biopharma Corporation share price today?

Arbutus Biopharma Corporation share price today is $4.55 as on at the close of the market. Arbutus Biopharma Corporation share today touched a day high of $4.65 and a low of $4.46.

What is the 52 week high and 52 week low for Arbutus Biopharma Corporation share?

Arbutus Biopharma Corporation share touched a 52 week high of $5.1 on and a 52 week low of $3.04 on . Arbutus Biopharma Corporation stock price today i.e. is closed at $4.55,which is 10.78% down from its 52 week high and 49.67% up from its 52 week low.

What is Arbutus Biopharma Corporation's market capitalisation today?

Arbutus Biopharma Corporation market capitalisation is $0.00T as on .

How to invest in Arbutus Biopharma Corporation Stock (ABUS) from India?

  1. Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
  2. Step 2: Search for Arbutus Biopharma Corporation on INDmoney app. Click on Buy button. You can invest as low as $1.5 in Arbutus Biopharma Corporation Shares that will get you 0.3297 shares as per Arbutus Biopharma Corporation share price of $4.55 per share as on June 19, 2026 at 8:45 am IST.

What is the minimum amount required to buy Arbutus Biopharma Corporation Stock (ABUS) from India?

Indian investors can start investing in Arbutus Biopharma Corporation (ABUS) shares with as little as ₹94.31 or $1 (as of ) using the INDmoney app.
For example: If you want to invest $10 or ₹943.10 in Arbutus Biopharma Corporation stock (as per the Rupee-Dollar exchange rate as on ). Based on Arbutus Biopharma Corporation share’s latest price of $4.55 as on June 19, 2026 at 8:45 am IST, you will get 2.1978 shares of Arbutus Biopharma Corporation. Learn more about fractional shares .

What are the returns that Arbutus Biopharma Corporation has given to Indian investors in the last 5 years?

Arbutus Biopharma Corporation stock has given 40% share price returns and 27.24% dollar appreciation to an Indian investor in the last 5 years.
Read more about How do Currency Exchange Rates impact your returns on US Stock Investments?